Psyence Biomedical Ltd. (PBM)
Psyence Biomedical Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $3.42, up 0.59% on the session, giving a market capitalisation of $65,045. On trailing twelve-month figures it carries a trailing P/E of 0.00, a net margin of 0.0%. Its beta of 1.67 implies it has historically moved more than the broad market.
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
Psyence Biomedical Ltd. is most often compared with the following Healthcare names: